Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.41 |
| ▸ | MEN1 | O00255 | 5/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4459057 | 0.88 | PRKCA (0.44) | KMT2AMEN1MAPT | |
| SCHEMBL7286996 | 0.82 | POLB (0.45) | KMT2AMEN1POLBMAPTLMNA | |
| SCHEMBL7559265 | 0.78 | KMT2A (0.50) | KMT2AMEN1NPSR1SMN1; SMN2TSHR | |
| SCHEMBL10919474 | 0.76 | KDM4E (0.38) | KMT2ASMN1; SMN2MAPTLMNASLC18A3 | |
| SCHEMBL10917834 | 0.74 | POLB (0.43) | KMT2AMEN1POLBALDH1A1 | |
| SCHEMBL27720908 | 0.73 | SSTR4 (0.40) | KMT2AMEN1NPSR1SMN1; SMN2TSHR | |
| SCHEMBL27864062 | 0.72 | POLB (0.47) | KMT2AMEN1NPSR1SMN1; SMN2TSHR | |
| SCHEMBL10918509 | 0.72 | PRKCA (0.45) | POLB | |
| SCHEMBL10915144 | 0.72 | PRKCA (0.45) | POLB | |
| SCHEMBL27535325 | 0.71 | ALDH1A1 (0.46) | KMT2AMEN1NPSR1SMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2837630-B1 | METHOD FOR SYNTHESIZING SAPROPTERIN DIHYDROCHLORIDE | ASYMCHEM LAB TIANJIN CO LTD (CN) | 2016-11-23 | — | — | EP | claimed |
| US-9371326-B2 | Method for synthesizing sapropterin dihydrochloride | ASYMCHEM LABORATORIES (TIANJIN) CO., LTD (CN) | 2016-06-21 | — | — | US | claimed |
| US-9365573-B2 | Method for synthesizing sapropterin dihydrochloride | ASYMCHEM LABORATORIES (TIANJIN) CO., LTD (CN) | 2016-06-14 | — | — | US | claimed |
| US-20150119573-A1 | METHOD FOR SYNTHESIZING SAPROPTERIN DIHYDROCHLORIDE | TIANJIN ASYMCHEM PHARMACEUTICAL CO., LTD (CN) | 2015-04-30 | — | — | US | claimed |
| US-20150105555-A1 | METHOD FOR SYNTHESIZING SAPROPTERIN DIHYDROCHLORIDE | TIANJIN ASYMCHEM PHARMACEUTICAL CO., LTD (CN) | 2015-04-16 | — | — | US | claimed |
| EP-2837629-A1 | METHOD FOR SYNTHESIZING SAPROPTERIN DIHYDROCHLORIDE | Asymchem Laboratories (Tianjin) Co., Ltd (CN) | 2015-02-18 | — | — | EP | claimed |
| EP-2837630-A1 | METHOD FOR SYNTHESIZING SAPROPTERIN DIHYDROCHLORIDE | Asymchem Laboratories (Tianjin) Co., Ltd (CN) | 2015-02-18 | — | — | EP | claimed |
| EP-2837630-B1 | METHOD FOR SYNTHESIZING SAPROPTERIN DIHYDROCHLORIDE | ASYMCHEM LAB TIANJIN CO LTD (CN) | 2016-11-23 | — | — | EP | disclosed |
| US-9371326-B2 | Method for synthesizing sapropterin dihydrochloride | ASYMCHEM LABORATORIES (TIANJIN) CO., LTD (CN) | 2016-06-21 | — | — | US | disclosed |
| US-9365573-B2 | Method for synthesizing sapropterin dihydrochloride | ASYMCHEM LABORATORIES (TIANJIN) CO., LTD (CN) | 2016-06-14 | — | — | US | disclosed |
| US-20150119573-A1 | METHOD FOR SYNTHESIZING SAPROPTERIN DIHYDROCHLORIDE | TIANJIN ASYMCHEM PHARMACEUTICAL CO., LTD (CN) | 2015-04-30 | — | — | US | disclosed |
| US-20150105555-A1 | METHOD FOR SYNTHESIZING SAPROPTERIN DIHYDROCHLORIDE | TIANJIN ASYMCHEM PHARMACEUTICAL CO., LTD (CN) | 2015-04-16 | — | — | US | disclosed |
| EP-2837629-A1 | METHOD FOR SYNTHESIZING SAPROPTERIN DIHYDROCHLORIDE | Asymchem Laboratories (Tianjin) Co., Ltd (CN) | 2015-02-18 | — | — | EP | disclosed |
| EP-2837630-A1 | METHOD FOR SYNTHESIZING SAPROPTERIN DIHYDROCHLORIDE | Asymchem Laboratories (Tianjin) Co., Ltd (CN) | 2015-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105555-A1 | METHOD FOR SYNTHESIZING SAPROPTERIN DIHYDROCHLORIDE | CYP51A1, DHCR7, LSS | KMT2A 4271/4885MEN1 1207/4885NPSR1 1105/4885 |
| US-20150119573-A1 | METHOD FOR SYNTHESIZING SAPROPTERIN DIHYDROCHLORIDE | DHCR7, CYP51A1, HMGCR | KMT2A 4568/4885MEN1 1018/4885NPSR1 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.